Intellia Therapeutics Enters $400 Million OrbiMed Term Loan Facility

09:18 AM EDT, 09/04/2026 (MT Newswires) -- Intellia Therapeutics (NTLA) entered a $400 million non-dilutive senior secured term loan facility with OrbiMed to support key clinical and commercial milestones, the company said Friday. The facility includes $75 million funded at closing, up to $225 million in milestone-based tranches primarily tied to lonvo-z, and an additional $100 million subject to mutual agreement, the company said. Intellia plans to use the financing to support a potential US approval and commercial launch of lonvo-z for hereditary angioedema, advance nexiguran ziclumeran in transthyretin amyloidosis and develop its early pipeline, it added.